Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Study of Safety, Tolerability, Pharmacokinetics and Activity of 14 Days of Oral Dosing With the 2S,4R Enantiomer of Ketoconazole (DIO-902) in Subjects With Type 2 Diabetes Mellitus

NCT00302224 is registered in ClinicalTrials.gov with DiObex as lead sponsor.

NCT NCT00302224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00302224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Study of Safety, Tolerability, Pharmacokinetics and Activity of 14 Days of Oral Dosing With the 2S,4R Enantiomer of Ketoconazole (DIO-902) in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
DiObex
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2005
Completion date
August 31, 2006
Enrollment
50
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes